The experience of using acetylsalicylic acid in a comorbid patient with cad and type 2 diabetes
https://doi.org/10.21518/2079-701X-2018-16-54-60
Abstract
The CVD death rates remain high now. The concurrent course of coronary artery disease (CAD) and diabetes mellitus (DM) has an unfavourable prognosis, requires specific therapy and the use of measures to prevent severe complications. DM sometimes hinders the timely diagnosis of CAD, which in this case is characterized by an atypical course and has no florid symptoms. This often causes serious pathological complications or death. The atherothrombosis forms the basis of pathogenesis of severe conditions. Atherothrombosis is not only a generalized, but also a constantly progressive disease, for which reason it is necessary to carry out both primary and secondary prevention. According to the existing guidelines of European Society of Cardiology and Society of Cardiology of Russian Federation, acetylsalicylic acid (ASA) is recommended at small doses as the first-line drug for the prevention of vascular events in patients with CAD. This article discusses the experience of using ASA according to the conducted studies and in practical medicine by the clinical example of a female patient.
About the Authors
G. N. Gorokhovskaya
Yevdokimov Moscow State University of Medicine and Dentistry, Federal State Budgetary Educational Institution of Higher Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
V. L. Yun
Yevdokimov Moscow State University of Medicine and Dentistry, Federal State Budgetary Educational Institution of Higher Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Yu. A. Vasyuk
Yevdokimov Moscow State University of Medicine and Dentistry, Federal State Budgetary Educational Institution of Higher Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
E. Yu. Maichuk
Yevdokimov Moscow State University of Medicine and Dentistry, Federal State Budgetary Educational Institution of Higher Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
A. I. Martynov
Yevdokimov Moscow State University of Medicine and Dentistry, Federal State Budgetary Educational Institution of Higher Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Health Care in Russia in 2015: http://www.gks.ru/free_doc/doc_2015/zdrav15.pdf.
2. Roth GA Forouzanfar MH, Moran AE et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med, 2015, 372(14): 1333-41.
3. Nishimura R, Nakagami T, Sone H et al. Relationship between hemoglobin A1c and cardiovascular disease in mild-to-moderate hypercholesterolemic Japanese individuals: subanalysis of a large-scale randomized controlled trial. Cardiovasc Diabetol, 2011, 10: 58.
4. Lenzen M, Ryden L, Ohrvik J et al. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J, 2006, 27: 2969–2974.
5. Ray KK, Cannon CP, McCabe CH et al. Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes. Results From the PROVE IT-TIMI 22 Trial. J Am Coll Cardiol, 2005, 46: 1405–10.
6. Wiviott SD, Cannon CP, Morrow DA et al. Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low. Low-Density Lipoprotein With Intensive Statin Therapy. A PROVE IT-TIMI 22 Substudy. J Am Coll Cardiol, 2005, 46: 1411–6.
7. Usacheva EV, Sukonchik AO. Comorbidity as a problem of the 21st century: cardiovascular diseases and diabetes mellitus. Meditsinskie Nauki, 2018, 85 (1): 248-254.
8. Sumarokov AB. Acetylsalicylic acid: an antiaggregant and anti-inflammatory agent in the therapy and prevention of cardiovascular diseases. Spravochnik Poliklinicheskogo Vracha, 2013, 10: 16-21.
9. Gorokhovskaya GN, Yun VL. Antiplatelet therapy: a contemporary view and comprehensive approach to the problem of atherothrombosis. RMJ, 2013, 34: 1737-1741.
10. Shilov AM. Aspirinantiaggregant in treatment of cardiovascular diseases. RMJ, 2012, 9 (12): 10-14.
11. Sumarokov AB. Acetylsalicylic acid is an antiaggregant and anti-inflammatory agent in the therapy and prevention of cardiovascular diseases. Spravochnik Poliklinicheskogo Vracha, 2013, 10: 16-21.
12. Aynetdinova DKh, Udovichenko AE, Sulimov VA. The role of antiplatelet therapy in primary and secondary prevention of cardiovascular diseases. Effektivnaya Farmakoterapiya v Kardiologii i Angiologii. 2007, 2: 36-41.
13. Kudryashova OYu, Zateeyshikov DA, Sidorenko BA. Genetic basis of individual sensitivity to antiplatelet drugs. Kardiologiya, 2005, 9 (45): 85-89.
14. Ostroumova OD. Prospects for using cardiomagnyl in patients with diabetes mellitus. RMJ, 2004, 12 (5): 350-354.
15. Ushkalova EA. Aspirin resistance: development mechanisms, diagnostic methods and clinical significance. Pharmateca, 2006, 13 (128): 35-41.
16. Chesnikova AI. How to increase treatment effectiveness of coronary artery disease: from aspirin to ticagrelor. Serdtse 2013, 10 (1): 3-11.
17. Garkina SV, Duplyakov DV, Pavlova ТV. Problems of using antiplatelet therapy in cardiology. Effektivnaya Farmakoterapiya, 2012, 1: 24-27.
18. Shilov AM. Two-component (ASA + clopidogrel) antithrombotic therapy of acute coronary syndrome in the primary care physician practice. RMJ, 2012, 20: 1070-1075.
19. Hart RG, Pearce LA, Aguilar MI. Mtta-analysis antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Inter Med, 2007, 146(12): 857–867.
20. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardialinfarction and stroke in highrisk patients. BMJ, 2002, 324: 71–86.
21. Gorya cheva EV, Rodionov AV, Sulimov VA. Antiaggre gant therapy in invasive management of acute coronary syndrome. Serdtse, 2011, 10 (4): 195-198.
22. Shalaev SV. Antiplatelet agents in the treatment of acute coronary syndromes. Pharmateca, 2003, 312: 94-97
23. Bhatt DL, Topol EJ. Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidence Executive Committee. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and hughrisk primary prevention: rational and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidence (CHARISMA) trial. Am Heart J, 2004, 148: 263–268.
24. Lupanov VP, Samko AN. Clopidogrel in the prevention of thrombotic complications in patients with coronary atherosclerosis after percutaneous coronary interventions (review). Consilium medicum, 2011, 5: 102-109.
25. Goryacheva EV, Rodionov AV, Sulimov VA. Antiaggregant therapy in invasive management of acute coronary syndrome. Serdtse, 2011, 10 (4): 195-198
26. Chesnikova AI. Prospects for increasing the effectiveness of treatment of coronary heart disease: from aspirin to ticagrelor. Serdtse, 2012, 1 (69): 3-11.
27. Vertkin AL, Zayratyants OV, Vovk EI, Kolobov SV. Treatment and prevention of gastrointestinal bleeding in a patient developing an acute exacerbation of coronary artery disease. Pharmateca, 2007, 15: 54-60.
28. Drouet L. Atherothrombosis as a systemic disease. Cerebrovasc Dis, 2002, 13(suppl 1): 1–6.
29. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation, 2001, 104: 365–372.
Review
For citations:
Gorokhovskaya GN, Yun VL, Vasyuk YA, Maichuk EY, Martynov AI. The experience of using acetylsalicylic acid in a comorbid patient with cad and type 2 diabetes. Meditsinskiy sovet = Medical Council. 2018;(16):54-60. (In Russ.) https://doi.org/10.21518/2079-701X-2018-16-54-60
Views:
734
Email this article 